Manso, L., Ciruelos, E., Codes, M., De la Haba, J., Galan, A., Baena, J., . . . Salvador, J. (2011). Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy. BioMed Central.
Chicago Style CitationManso, L., et al. Prognostic Value of a High Level of Circulating Endothelial Cells in Patients With HER2-recurrent or Metastatic Breast Cancer Treated With Bevacizumab in Combination With Paclitaxel and Gemcitabine As First-line Therapy. BioMed Central, 2011.
MLA CitationManso, L., et al. Prognostic Value of a High Level of Circulating Endothelial Cells in Patients With HER2-recurrent or Metastatic Breast Cancer Treated With Bevacizumab in Combination With Paclitaxel and Gemcitabine As First-line Therapy. BioMed Central, 2011.